Literature DB >> 29459010

Plasma microRNA signature of patients with IgA nephropathy.

Jingjing Wu1, Huo Zhang2, Weiwei Wang3, Mingxia Zhu4, Lian-Wen Qi5, Tongshan Wang2, Wenfang Cheng6, Jun Zhu7, Xia Shan8, Zebo Huang2, Lan Zhang2, Yan Chen9, Bin Sun1, Xiufen Zhao1, Jun Qian1, Wei Zhu10, Xin Zhou11, Changying Xing12.   

Abstract

We looked for differentially expressed MicroRNAs (miRNAs) in Immunoglobulin A nephropathy (IgAN). Forty-eight miRNAs were identified through the initial screening phase (2 IgAN pools vs. 1 normal control (NC) pool) using quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel (miRCURY-Ready-to-Use-PCR-Human-panel-I + II-V1.M). By qRT-PCR, these miRNAs were further assessed in the training (32 IgAN VS. 31 NCs) and testing stages (51 IgAN VS. 51 NCs). The renal pathological lesions of patients with IgAN were evaluated according to Lee's grading system. We discovered a plasma miRNA signature including four up-regulated miRNAs (miR-148a-3p, miR-150-5p, miR-20a-5p and miR-425-3p) and the areas under the receiver operating characteristic (ROC) curve (AUC) were 0.80 and 0.76 for the training and testing stage, respectively. The expression of the four miRNAs in IgAN grade I-II subgroups (according to Lee's grading system) was obviously higher than that in IgAN grade III-V (P < .05). In summary, the plasma expression of miR-148a-3p, miR-150-5p, miR-20a-5p and miR-425-3p were up-regulated in patients with IgAN, especially the early-stage disease. Further studies are needed to explore the roles of the four miRNAs in the pathogenesis and progression of IgAN.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Diagnosis; IgA nephropathy; Microarray; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29459010     DOI: 10.1016/j.gene.2018.01.050

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy.

Authors:  Ziyan Wang; Yu Liao; Lixin Wang; Yanzhao Lin; Ziyi Ye; Xufang Zeng; Xiaorou Liu; Fangning Wei; Nizhi Yang
Journal:  Mol Med Rep       Date:  2020-08-03       Impact factor: 2.952

2.  Five serum microRNAs for detection and predicting of ovarian cancer.

Authors:  Weiwei Wang; Li-Rong Wu; Chunyu Li; Xin Zhou; Ping Liu; Xuemei Jia; Yan Chen; Wei Zhu
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-04-06

Review 3.  The Role of MicroRNAs in Selected Forms of Glomerulonephritis.

Authors:  Magdalena Nalewajska; Klaudia Gurazda; Ewa Styczyńska-Kowalska; Małgorzata Marchelek-Myśliwiec; Andrzej Pawlik; Violetta Dziedziejko
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

4.  Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.

Authors:  Yuzhu Ma; Daolu Yuwen; Jingwei Chen; Bingfeng Zheng; Jian Gao; Minmin Fan; Wenwen Xue; Yixuan Wang; Wuhao Li; Yongqian Shu; Qiang Xu; Yan Shen
Journal:  Int J Nanomedicine       Date:  2019-10-07

5.  Altered expression of serum miR-106a, miR-19b, miR-17, and PTEN in patients with idiopathic membranous nephropathy.

Authors:  Lina Wu; Xinpeng Zhang; Lin Luo; Xiaoying Li; Yong Liu; Xiaosong Qin
Journal:  J Clin Lab Anal       Date:  2021-03-21       Impact factor: 2.352

Review 6.  MicroRNAs in IgA nephropathy.

Authors:  Xingchen Yao; Yaling Zhai; Huanping An; Jingge Gao; Yazhuo Chen; Wenhui Zhang; Zhanzheng Zhao
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 7.  MicroRNAs as Potential Biomarkers for the Diagnosis of Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Jing Li; Leilei Ma; Hangxing Yu; Yahong Yao; Zhiyuan Xu; Wei Lin; Lin Wang; Xuejun Wang; Hongtao Yang
Journal:  Front Med (Lausanne)       Date:  2022-02-07

Review 8.  The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?

Authors:  Izabella Z A Pawluczyk; Haresh Selvaskandan; Jonathan Barratt
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.